Abstracts tagged "Clinical practice"

Abstract Number: 3181 • 2015 ACR/ARHP Annual Meeting
How Common Is Inactive Disease in a Prospective Cohort of Patients with Juvenile Idiopathic Arthritis? the Importance of Definition
Stephanie Shoop¹, Suzanne M. Verstappen², Eileen Baildam³, Alice Chieng⁴, Joyce Davidson^5,6, Helen Foster⁷, Yiannis Ioannou⁸, Flora McErlane⁷, Lucy R Wedderburn⁹, Wendy Thomson¹⁰ and Kimme L. Hyrich¹⁰, ¹ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, The University of Manchester, M13 9PT, United Kingdom, ²ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, the University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁵The Royal Hospital for Sick Children, Glasgow, Glasgow, United Kingdom, ⁶The Royal Hospital for Sick Children, Edinburgh, Edinburgh, United Kingdom, ⁷Royal Victoria Hospital, Newcastle, United Kingdom, ⁸Rayne Institute, University College London, London, UK, London, United Kingdom, ⁹Great Ormond Street Hospital NHS Foundation Trust, Paediatric Rheumatology, London, United Kingdom, ¹⁰arc Epidemiology Unit, Manchester, United Kingdom
Background/Purpose: Patients with JIA are at risk of disability, pain and joint damage in the longer-term. Treating toward clinically inactive disease (ID) has the potential…
Abstract Number: 504 • 2015 ACR/ARHP Annual Meeting
Influence of CDAI Measurement on the Decision of Community Rheumatologists to Initiate or Change Biologic Treatment
Alan K. Matsumoto¹, Herbert S. B. Baraf², Janna Radtchenko³, Jason Drenning⁴ and Bruce Feinberg⁵, ¹Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, ²The Center for Rheumatology and Bone Research, Wheaton, MD, ³Health Care Analytics, Cardinal Health, Dallas, TX, ⁴Healthcare Analytics, Cardinal health, Dallas, TX, ⁵Cardinal Health, Dublin, OH
Background/Purpose: Periodic measurement of disease activity using validated tools such as the Clinical Disease Activity Index (CDAI) is considered an important aspect of care for…
Abstract Number: 3185 • 2015 ACR/ARHP Annual Meeting
A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients in the United States
Leslie Harrold^1,2, George W. Reed^1,2, J. Timothy Harrington³, Christine J. Barr¹, Katherine C. Saunders¹, Allan Gibofsky⁴, Eric M. Ruderman⁵, Tmirah Haselkorn⁶, Jeffrey D. Greenberg^1,7, Ani John⁶ and Joel M. Kremer⁸, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Joiner Associates, LLC, Madison, WI, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY, ⁸Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: We report the results of a cluster-randomized behavioral intervention trial designed to assess the impact of implementing a treat-to-target (T2T) approach vs usual care…
Abstract Number: 506 • 2015 ACR/ARHP Annual Meeting
Evaluation of Persistence and Outcomes in Patients Treated with TNF and Non-TNF Biologics Following Treatment Clinical Pathway in Rheumatoid Arthritis
Alan K. Matsumoto¹, Herbert S. B. Baraf², Janna Radtchenko³, Jason Drenning⁴ and Bruce Feinberg⁵, ¹Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, ²The Center for Rheumatology and Bone Research, Wheaton, MD, ³Health Care Analytics, Cardinal Health, Dallas, TX, ⁴Healthcare Analytics, Cardinal health, Dallas, TX, ⁵Cardinal Health, Dublin, OH
Background/Purpose: Use of biologic agents for the treatment of rheumatoid arthritis continues to grow rapidly, with the cost of these agents putting a significant strain…
Abstract Number: 580 • 2015 ACR/ARHP Annual Meeting
Treatment with Biologic Agents in Rheumatoid Arthritis and Mortality Risk in Clinical Practice
Leticia Leon¹, Luis Rodriguez-Rodriguez¹, Alejandro Gomez-Gomez², Pilar Macarrón², Margarita Blanco², Juan A Jover² and Lydia Abasolo¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: It is a well-known fact the decline of life expectancy in Rheumatoid Arthritis (RA) being the increased mortality in these patients a constant concern…
Abstract Number: 682 • 2015 ACR/ARHP Annual Meeting
Misalignment Between Physician and Patient Satisfaction with Current Psoriatic Arthritis Treatment
Daniel E. Furst¹, Emma Sullivan², James Pike³, James Piercy⁴, Jacqueline Palmer⁵ and Vivian Herrera⁵, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Adelphi Real World, Manchester, United Kingdom, ³Statistics, Adelphi Real World, Macclesfield, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic immune related condition affecting the joints and commonly occurs alongside psoriasis. Well-established physician patient relationships are instrumental to…
Abstract Number: 1276 • 2015 ACR/ARHP Annual Meeting
Improvement in Work and Household Productivity for Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with Anti-TNFs in Routine Clinical Practice in Turkey
Sebnem Ataman¹, Mehmet Kirnap², Buminhan Seferoglu³, Zuhal Altay⁴, Aylin Rezvani⁵, Omer Kuru^6,7, Erhan Capkin⁸, Nazli Derya Bugdayci⁹, Ilhan Sezer¹⁰, Hasan Fatih CAY¹¹ and Akinci Tan¹², ¹Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey, ²Department of Physical Medicine and Rehabilitation, Erciyes University, Kayseri, Turkey, ³Physical Medicine and Rehabilitation, Ataturk University Medical School, Erzurum, Turkey, ⁴ELAZIG KARAYOLU UZERI, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey, ⁵Department of Physical Medicine and Rehabilitation, Bezmialem Foundation University, İstanbul, Turkey, ⁶Kurupelit Mevkii Kurupelit 552, Ondokuz Mayis Univ.Tip Fak.Has.-Fizik Tedavi, Samsun, Turkey, ⁷Physical Medicine and Rehabilitation, Ondokuz Mayis University, Samsun, Turkey, ⁸PM&R AND RHEUMATOLOGY, Karadeniz Tecnical University, Faculty of Medicine, TRABZON, Turkey, ⁹Physical Treatment and Rehabilitation, Istanbul Physical Treatment and Rehabilitation Training and Research Hospital, Istanbul, Turkey, ¹⁰Rheumatology, Physical Medicine and Rheabilitation, Antalya Education and Research Hospital, Antalya, Turkey, ¹¹Rheumatology, Physical Medicine&Rehabilitation, Antalya Education and Research Hospital, Antalya, Turkey, ¹²Physical Med & Rehab, Hacettepe Univ, Ankara, Turkey
Background/Purpose: The impact of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) on paid work is measured on the basis of employed people missing time from…
Abstract Number: 2499 • 2014 ACR/ARHP Annual Meeting
Early Response Indicator early Predicts Clinical Response to Certolizumab in Rheumatoid Arthritis Patients
Massimiliano Cazzato¹, Laura Bazzichi², Stefano Bombardieri³ and Camillo Giacomelli⁴, ¹Internal Medicine, Rheumatology Unit, Pisa, Italy, ²Santa Chiara Hospital, Rheumatology, pisa, Italy, ³Rheumatology Unit, Pisa, Italy, ⁴Rheumatology, pisa, Italy
Background/Purpose In the last few years the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…
Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting
Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus
Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…
Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting
Durability of First Biologic Is Not Influenced By Initial/Early DAS28
Gina Rohekar¹, Binu Jacob², Janet E. Pope³ and Claire Bombardier⁴, ¹Rheumatology, St. Joseph's Hospital, London, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Western University, London, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting. Patients are enrolled and prospectively followed to…
Abstract Number: 424 • 2014 ACR/ARHP Annual Meeting
The Comparison Between Physical and Ultrasound Joint Examination for the Hand Joints in Patients with Rheumatoid Arthritis
Norihide Hayashi¹, Takehisa Ogura², Ayako Hirata², Rie Kujime³, Munetsugu Imamura¹, Sayaka Takenaka³, Kennosuke Mizushina³, Sumie Nakahashi³, Hideki Ito¹, Naoko Yamashita³ and Hideto Kameda¹, ¹Div Rheumatol, Dep Intern Med, Toho Univ, Tokyo, Japan, ²Department of Rheumatology, Toho Univ, Tokyo, Japan, ³Toho Univ, Tokyo, Japan
Background/Purpose To establish the importance of joint examination by ultrasound (US) in daily clinical practice of patients with rheumatoid arthritis (RA), we compared the US…
Abstract Number: 2384 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Methotrexate Treatment Duration, Including Subcutaneous Use, in Patients with Rheumatoid Arthritis: Observations from the VA Database
Bernard Ng, Rheumatology, U.S. Department of Veterans' Affairs- Puget Sound Healthsystem, Seattle, WA
Background/Purpose: A previous analysis of RA patients in national administrative databases of the Department of Veterans Affairs (VA) suggested that injectable MTX was associated with…
Abstract Number: 430 • 2014 ACR/ARHP Annual Meeting
Minimally Important Difference in the European Quality of Life-Five Dimensions in Patients with Rheumatoid Arthritis
Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Kumi Shidara, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Patient-reported outcomes (PROs) have been recognized as important in evaluating disease status of rheumatoid arthritis (RA). The minimally important difference (MID) in PROs has…
Abstract Number: 2366 • 2014 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Subcutaneous Methotrexate in Early Rheumatoid Arthritis: Clinical Data from the St. Gallen Cohort
Ruediger Mueller¹, Johannes von Kempis¹, Michael H Schiff² and Sarah Haile³, ¹Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland, ²University of Colorado, Denver, CO, ³Division of Biostatistics, Institute for Social and Preventive Medicine,, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: MTX is the cornerstone of RA treatment, although limitations of systemic exposure of oral MTX may affect its efficacy. Subcutaneous (SC) MTX has greater…
Abstract Number: 265 • 2014 ACR/ARHP Annual Meeting
Prevalence of Medicinal Marijuana Use Among 1000 Rheumatology Patients Attending a Community-Based Rheumatology Clinic: A Prospective Cross-Sectional Study
Peter A. Ste-Marie¹, Yoram Shir¹, Emmanouil Rampakakis², John S. Sampalis^2,3, Martin Cohen⁴, Michael Starr⁵, Mark A Ware¹ and Mary-Ann Fitzcharles⁶, ¹Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁴Rheumatology, Mcgill University Health Centre, Montreal, QC, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶Rheumatology and Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: With a worldwide groundswell of interest in cannabinoids as a possible treatment option for persons with rheumatic diseases, and with few pharmacologic cannabinoid options…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.